Advanced

Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension

Lunell, N O; Bondesson, U; Grunewald, C; Ingemarsson, Ingemar LU ; Nisell, H and Wide-Swensson, Dag LU (1993) In American Journal of Hypertension 6(3 Pt 2). p.110-111
Abstract
The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group... (More)
The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group and 45 +/- 14 pg/mL in the SRO group. Therefore, isradipine passes the placental barrier, but its concentration is considerably lower in the fetal compartments. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Hypertension
volume
6
issue
3 Pt 2
pages
110 - 111
publisher
Elsevier
external identifiers
  • pmid:8466718
  • scopus:0027534499
ISSN
1941-7225
language
English
LU publication?
yes
id
fc59f2d2-a4b9-45a1-a38d-7778a7dffd2f (old id 1107602)
date added to LUP
2008-07-31 13:10:57
date last changed
2017-01-01 04:53:13
@article{fc59f2d2-a4b9-45a1-a38d-7778a7dffd2f,
  abstract     = {The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group and 45 +/- 14 pg/mL in the SRO group. Therefore, isradipine passes the placental barrier, but its concentration is considerably lower in the fetal compartments.},
  author       = {Lunell, N O and Bondesson, U and Grunewald, C and Ingemarsson, Ingemar and Nisell, H and Wide-Swensson, Dag},
  issn         = {1941-7225},
  language     = {eng},
  number       = {3 Pt 2},
  pages        = {110--111},
  publisher    = {Elsevier},
  series       = {American Journal of Hypertension},
  title        = {Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension},
  volume       = {6},
  year         = {1993},
}